On 10/25/24, Revance Therapeutics Inc (NASDAQ: RVNC) stock suffered a major decline of -11.3%, closing at $4.70. However, below average trading volume at 80% of normal accompanied the decline. The stock has declined -9.3% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
RVNC’s future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to be a modest Value Eraser.
Revance Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment